UK faces more than £20bn hit from steeper productivity downgrade, fuelling tax rise speculation – business live | Business


Reeves faces £20bn-plus hit from UK productivity cut

Here’s our full story: Rachel Reeves will have to account for a bigger-than-expected £20bn hit to the public finances in next month’s budget, the Guardian understands, as the Treasury’s forecaster prepares to cut predictions for UK productivity.

The Office for Budget Responsibility (OBR) is planning to cut its trend productivity growth prediction by 0.3 percentage points, in a move that increases the likelihood of the chancellor announcing tax rises on 26 November.

Reeves told the Fortune Forum in Saudi Arabia on Monday:

Our independent forecaster is likely to downgrade the forecast for productivity in the UK based not on anything this government has done, but on our past productivity numbers, which, to be honest, since the financial crisis and Brexit have been very poor, and that just shows how essential growth is.

So I’m not going to do anything in the budget that reduces our opportunities to grow the economy. That’s very important.

The estimated impact is based on calculations by the Institute for Fiscal Studies (IFS) thinktank, first reported in the Financial Times, which has said that each 0.1-percentage-point downgrade to productivity would increase public sector net borrowing by £7bn in 2029-30. That suggests that a 0.3-point reduction could result in a £21bn hit to the public finances.

Some analysts had been forecasting a 0.1 to 0.2-point downgrade in the OBR’s productivity outlook, resulting in smaller hit to the public finances of between £7bn and £14bn, based on IFS calculations. This would result in a total fiscal hole of £20bn to £30bn, according to some estimates.

A larger downgrade to productivity by the OBR would increase that shortfall. However, the final number could be offset by other factors including lower borrowing costs and faster-than-expected growth.

Share

Updated at 

Key events

Britain’s second-biggest drugmaker GSK has struck another deal to bolster its pipeline of medicines, a day before announcing its quarterly results, the last presented by outgoing chief executive Emma Walmsley.

The company has acquired a treatment for COPD, a severe lung disease, that is in early clinical studies, from the Californian biotech Empirico.

GSK said the drug’s novel mechanism of action, discovered by Empirico, targets a distinct inflammatory pathway introducing the potential for a therapeutic approach that is agnostic of baseline type 2 inflammation, smoking or co-morbid disease. The target is backed by extensive genetic data.

Kaivan Khavandi, global head of respiratory, immunology & inflammation research & development at GSK, said:

This agreement reflects our ambition to transform care in COPD by advancing novel targets, backed by data, to address underlying drivers of disease. With its expected long-acting characteristics and ability to target distinct inflammatory pathways, EMP-012 complements our pipeline of diverse modalities in COPD and builds on the current landscape of inhaled and biologic therapeutics in this area of substantial unmet need.

GSK will pay $85m upfront and up to $660m in success-based development, regulatory and commercial milestones, as well as tiered royalties on sales worldwide.

Yesterday, GSK struck a deal for a prostate cancer medication from a French biotech firm.

Separately, the pharma firm’s treatment for small-cell lung cancer has received orphan drug designation in the EU, as it addresses a significant unmet need for an aggressive form of lung cancer with poor outcomes and limited treatment options, GSK said. The status, awarded to medicines for rare conditions, means the drug can benefit from incentives such as protection from competition once on the market.

Share

Updated at 



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *